Open AccessFactors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy
Author(s) -
C. Mignard,
Maud MahoVaillant,
Marie-Laure Golinski,
Pierre Balayé,
C. ProstSquarcioni,
Estelle Houivet,
Sé Bastien Calbo,
B. Labeille,
C. PicardDahan,
Maria Polina Konstantinou,
G. Chaby,
M.A. Richard,
JeanDavid Bouaziz,
S. DuvertLehembre,
E. Delaporte,
Philippe Bernard,
F. Caux,
M. Alexandre,
S. Oro,
P. Vabres,
G. Quéreux,
A. Dupuy,
S. Debarbieux,
M. AvenelAudran,
M. D’Incan,
C. Bédane,
N. Bénéton,
D. Jullien,
N. Dupin,
L. Misery,
L. Machet,
M. BeylotBarry,
O. Dereure,
B. Sassolas,
Jacques Bénichou,
P. Joly,
V. Hébert,
Sébastien Calbo
Publication year - 2020
Publication title -
jama dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.128
H-Index - 166
eISSN - 2168-6084
pISSN - 2168-6068
DOI - 10.1001/jamadermatol.2020.0290
Subject(s) - medicine , rituximab , pemphigus , prednisone , regimen , randomized controlled trial , dermatology , lymphoma
Rituximab and short-term corticosteroid therapy are the criterion standard treatments for patients with newly diagnosed moderate to severe pemphigus.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom